• Publications
  • Influence
Design and development of a peptide-based adiponectin receptor agonist for cancer treatment
BackgroundAdiponectin, a fat tissue-derived adipokine, exhibits beneficial effects against insulin resistance, cardiovascular disease, inflammatory conditions, and cancer. Circulating adiponectinExpand
  • 124
  • 9
Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome
Placental protein 13 (PP13) is a galectin expressed by the syncytiotrophoblast. Women who subsequently develop preterm pre-eclampsia have low first trimester maternal serum PP13 concentrations. ThisExpand
  • 93
  • 6
Syndecan-1 and FGF-2, but Not FGF Receptor-1, Share a Common Transport Route and Co-Localize with Heparanase in the Nuclei of Mesenchymal Tumor Cells
Syndecan-1 forms complexes with growth factors and their cognate receptors in the cell membrane. We have previously reported a tubulin-mediated translocation of syndecan-1 to the nucleus. TheExpand
  • 59
  • 6
  • PDF
Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer.
Understanding the details of the molecular mechanism of tumor dissemination revealed that several proteoglycan species are involved in the process but their role can be described as Janus-faced. OneExpand
  • 95
  • 4
Remodeling of extracellular matrix by normal and tumor-associated fibroblasts promotes cervical cancer progression
BackgroundComparison of tissue microarray results of 29 cervical cancer and 27 normal cervix tissue samples using immunohistochemistry revealed considerable reorganization of the fibrillar stroma ofExpand
  • 59
  • 3
  • PDF
Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.
Triple-negative breast cancers, which represent 10-20% of all mammary tumours, are characterised by the aggressive phenotype, are often found in younger women and have been associated with poorExpand
  • 90
  • 3
Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas.
Syndecan-1, a transmembrane proteoglycan, may exert anti-proliferative effects and promote cell growth by binding various growth factors. Malignant epithelial cells often down-regulate their ownExpand
  • 44
  • 3
Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia
Preeclampsia is a disease of the mother, fetus, and placenta, and the gaps in our understanding of the complex interactions among their respective disease pathways preclude successful treatment andExpand
  • 63
  • 3
Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.
In this study, we assessed the changes and prognostic relevance of syndecan-1 (SDC1) tissue and serum levels in bladder cancer (BC). SDC1 levels were analyzed in 213 samples (119 paraffin-embeddedExpand
  • 37
  • 3
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas
Urachal cancer (UrC) is a rare but aggressive malignancy often diagnosed in advanced stages requiring systemic treatment. Although cytotoxic chemotherapy is of limited effectiveness, prospectiveExpand
  • 20
  • 3
...
1
2
3
4
5
...